CIDOFOVIR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cidofovir, and what generic alternatives are available?
Cidofovir is a drug marketed by Avet Lifesciences and Mylan Institutional and is included in two NDAs.
The generic ingredient in CIDOFOVIR is cidofovir. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cidofovir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cidofovir
A generic version of CIDOFOVIR was approved as cidofovir by MYLAN INSTITUTIONAL on June 27th, 2012.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CIDOFOVIR?
- What are the global sales for CIDOFOVIR?
- What is Average Wholesale Price for CIDOFOVIR?
Summary for CIDOFOVIR
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Clinical Trials: | 43 |
| Patent Applications: | 4,403 |
| Drug Prices: | Drug price information for CIDOFOVIR |
| DailyMed Link: | CIDOFOVIR at DailyMed |
Recent Clinical Trials for CIDOFOVIR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Biotest | Phase 2 |
| Assistance Publique - Hôpitaux de Paris | Phase 3 |
| University Hospital, Lille | Phase 2 |
Pharmacology for CIDOFOVIR
| Drug Class | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor |
| Mechanism of Action | DNA Polymerase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for CIDOFOVIR
US Patents and Regulatory Information for CIDOFOVIR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avet Lifesciences | CIDOFOVIR | cidofovir | INJECTABLE;INJECTION | 202501-001 | Jul 26, 2012 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan Institutional | CIDOFOVIR | cidofovir | INJECTABLE;INJECTION | 201276-001 | Jun 27, 2012 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for CIDOFOVIR
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences International Limited | Vistide | cidofovir | EMEA/H/C/000121 Vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Vistide should be used only when other agents are considered unsuitable., |
Withdrawn | no | no | no | 1997-04-23 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
